World's Best Scientists 2026 revealed!
Gordon J. Freeman

Gordon J. Freeman

Award Badge
Best Scientists
2025
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
196
Citations
162394
World Ranking
341
National Ranking
226

Immunology

D-Index
201
Citations
173278
World Ranking
11
National Ranking
6

Medicine

D-Index
201
Citations
173535
World Ranking
178
National Ranking
118

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2020 - Fellow, National Academy of Inventors
  • 2017 - Warren Alpert Foundation Prize For their collective contributions to the pre-clinical foundation and development of immune checkpoint blockade, a novel form of cancer therapy that has transformed the landscape of cancer treatment.

Overview

Gordon J. Freeman is affiliated with Harvard University in the United States. Their research primarily focuses on the fields of medicine and immunology and microbiology, with significant contributions in immunology, oncology, and molecular biology. Their work also intersects areas such as pulmonary and respiratory medicine and cancer research.

The scientist's main research topics include cancer immunotherapy and biomarkers, immune cell function and interaction, immunotherapy and immune responses, CAR-T cell therapy research, immune cells in cancer, T-cell and B-cell immunology, and renal cell carcinoma treatment.

Gordon J. Freeman has contributed extensively to several publication venues, most notably:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research
  • Cancer Immunology Research
  • Nature

Frequent coauthors collaborating with Freeman include:

  • Arlene H. Sharpe
  • Toni K. Choueiri
  • Sabina Signoretti
  • David F. McDermott
  • Catherine J. Wu

Selected recent papers authored or coauthored by Freeman are as follows:

  • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma, 2020, Nature Medicine
  • The importance of exosomal PDL1 in tumour immune evasion, 2020, Nature Reviews Immunology
  • Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis, 2021, Cell
  • Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy, 2020, Nature Cell Biology
  • Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells, 2022, Cell Metabolism

Freeman's contributions have been recognized with awards such as the Fellow of the National Academy of Inventors in 2020 and the Warren Alpert Foundation Prize in 2017, awarded for collective contributions to the development of immune checkpoint blockade as a cancer therapy.

Best Publications

  • PD-1 and its ligands in tolerance and immunity

    Mary E. Keir;Manish J. Butte;Gordon J. Freeman;Arlene H. Sharpe

  • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

    Gordon J. Freeman;Andrew J. Long;Yoshiko Iwai;Karen Bourque

  • Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

    Peng Jiang;Shengqing Gu;Deng Pan;Jingxin Fu

  • Restoring function in exhausted CD8 T cells during chronic viral infection.

    Daniel L. Barber;E. John Wherry;David Masopust;Baogong Zhu

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • PD-L2 is a second ligand for PD-1 and inhibits T cell activation

    Yvette Latchman;Clive R. Wood;Tatyana Chernova;Divya Chaudhary

  • PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

    Cheryl L Day;Daniel E Kaufmann;Photini Kiepiela;Julia A Brown

  • THE B7 FAMILY REVISITED

    Rebecca J. Greenwald;Gordon J. Freeman;Arlene H. Sharpe

  • CTLA-4 can function as a negative regulator of T cell activation

    Theresa L. Walunas;Deborah J. Lenschow;Christina Y. Bakker;Peter S. Linsley

  • CD4+CD25high Regulatory Cells in Human Peripheral Blood

    Clare Baecher-Allan;Julia A. Brown;Gordon J. Freeman;David A. Hafler

  • The B7–CD28 superfamily

    Arlene H Sharpe;Gordon J Freeman

  • Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

    Shawn D Blackburn;Haina Shin;W Nicholas Haining;W Nicholas Haining;Tao Zou

  • PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

    Loise Marie Francisco;Victor H. Salinas;Keturah Elise Brown;Vijay K. Vanguri;Vijay K. Vanguri

  • Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

    Matthew M. Gubin;Xiuli Zhang;Heiko Schuster;Etienne Caron

  • Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

    Manish J. Butte;Mary E. Keir;Theresa B. Phamduy;Arlene H. Sharpe

  • Defining CD8 + T cells that provide the proliferative burst after PD-1 therapy

    Se Jin Im;Masao Hashimoto;Michael Y Gerner;Michael Y Gerner;Junghwa Lee

  • Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease

    Laurent Monney;Catherine A. Sabatos;Jason L. Gaglia;Akemi Ryu

  • The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

    Arlene H Sharpe;E John Wherry;Rafi Ahmed;Gordon J Freeman

  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

    Shohei Koyama;Esra A. Akbay;Yvonne Y. Li;Grit S. Herter-Sprie

  • Combination cancer immunotherapy and new immunomodulatory targets.

    Kathleen M. Mahoney;Paul D. Rennert;Gordon J. Freeman

  • Tissue expression of PD-L1 mediates peripheral T cell tolerance

    Mary E. Keir;Spencer C. Liang;Indira Guleria;Yvette E. Latchman

Frequent Co-Authors

Arlene H. Sharpe
Arlene H. Sharpe Harvard University
Lee M. Nadler
Lee M. Nadler Harvard University
Vassiliki A. Boussiotis
Vassiliki A. Boussiotis Beth Israel Deaconess Medical Center
Scott J. Rodig
Scott J. Rodig Harvard University
Rosemarie H. DeKruyff
Rosemarie H. DeKruyff Stanford University
Rafi Ahmed
Rafi Ahmed Emory University
Sabina Signoretti
Sabina Signoretti Brigham and Women's Hospital
John G. Gribben
John G. Gribben Queen Mary University of London
Dale T. Umetsu
Dale T. Umetsu Stanford University
F. Stephen Hodi
F. Stephen Hodi Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Immunology often leads students to explore complementary healthcare fields, including advanced nursing roles. For those interested in transitioning into specialized nursing, programs like cheapest psych np programs offer cost-effective pathways to become psychiatric nurse practitioners.

For nurses aiming to elevate their qualifications, understanding the financial outlook is crucial. Insights into the doctor of nursing practice salary by state help guide career decisions, balancing educational investments with potential earnings.

Specialization is key in nursing, and many professionals look to advanced acute care roles. Programs designed to support this transition are well-explained in resources outlining acnp programs, enabling family nurse practitioners to become Acute Care Nurse Practitioners.

Additionally, accelerated pathways like accelerated rn to np programs make it possible for registered nurses to fast-track their journey toward becoming nurse practitioners, complementing their background in immunology and healthcare.

Best Scientists Citing Gordon J. Freeman

Trending Scientists